A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Newly Diagnosed Glioblastoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Age = 18 years with life expectancy > 12 weeks. 2) Histologically proven, newly diagnosed supratentorial glioblastoma (IDH mutant is excluded) based on the WHO classification (2016) which includes gliosarcoma (GS); prior diagnosis of lower grade astrocytoma that has been upgraded to histologically confirmed glioblastoma is eligible if chemotherapy and radiation therapy treatment-naïve. 3) Craniotomy site must be adequately healed, free of drainage or cellulitis and the underlying cranioplasty must appear intact prior to start of study treatment.
You may not be eligible for this study if the following are true:
-
1) Unable to swallow tablets or capsules. 2) Pregnant or breastfeeding. 3) Glioblastoma IDH mutant. 4) Prior radiation therapy to the brain.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
